{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:34:14Z","timestamp":1780432454106,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00105-024-05375-y","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T11:03:31Z","timestamp":1718276611000},"page":"623-628","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapie der chronischen Prurigo: Update und Perspektive","Treatment of chronic prurigo: update and perspectives"],"prefix":"10.1007","volume":"75","author":[{"given":"F.","family":"Witte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zeidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"5375_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jid.2022.08.042","volume":"143","author":"K Agelopoulos","year":"2023","unstructured":"Agelopoulos\u00a0K, Renkhold\u00a0L, Wiegmann\u00a0H et\u00a0al (2023) Transcriptomic, epigenomic, and neuroanatomic signatures differ in chronic prurigo, atopic dermatitis, and brachioradial pruritus. J\u00a0Invest Dermatol 143:264\u2013272.e3","journal-title":"J Invest Dermatol"},{"key":"5375_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaci.2023.04.019","volume":"152","author":"N Alkon","year":"2023","unstructured":"Alkon\u00a0N, Assen\u00a0FP, Arnoldner\u00a0T et\u00a0al (2023) Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis. J\u00a0Allergy Clin Immunol 152:420\u2013435","journal-title":"J Allergy Clin Immunol"},{"key":"5375_CR3","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1111\/jdv.17485","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin\u00a0M, Garbe\u00a0C, Hagenstr\u00f6m\u00a0K et\u00a0al (2021) Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: a\u00a0population-based claims data analysis. J\u00a0Eur Acad Dermatol Venereol 35:2270\u20132276","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5375_CR4","first-page":"822","volume":"21","author":"M Augustin","year":"2023","unstructured":"Augustin\u00a0M, Zeidler\u00a0C, von Kiedrowski\u00a0R et\u00a0al (2023) Indikation zur Systemtherapie bei chronischer Prurigo: Kommentierte Checkliste f\u00fcr die Praxis. J\u00a0Dtsch Dermatol Ges 21:822\u2013824","journal-title":"J Dtsch Dermatol Ges"},{"key":"5375_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2340\/00015555-2232","volume":"96","author":"S Bobko","year":"2016","unstructured":"Bobko\u00a0S, Zeidler\u00a0C, Osada\u00a0N et\u00a0al (2016) Intraepidermal nerve fibre density is decreased in lesional and inter-lesional prurigo nodularis and reconstitutes on healing of lesions. Acta Derm Venereol 96:404\u2013406","journal-title":"Acta Derm Venereol"},{"key":"5375_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jdv.15145","volume":"33","author":"E Brenaut","year":"2019","unstructured":"Brenaut\u00a0E, Halvorsen\u00a0JA, Dalgard\u00a0FJ et\u00a0al (2019) The self-assessed psychological comorbidities of prurigo in European patients: a\u00a0multicentre study in 13\u00a0countries. J\u00a0Eur Acad Dermatol Venereol 33:157\u2013162","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5375_CR7","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.jid.2023.05.011","volume":"143","author":"A Calugareanu","year":"2023","unstructured":"Calugareanu\u00a0A, Specque\u00a0F, Demouche\u00a0S et\u00a0al (2023) Transcriptomic landscape of prurigo nodularis lesional skin CD3+ T cells using single-cell RNA sequencing. J\u00a0Invest Dermatol 143:2525\u20132529.e5","journal-title":"J Invest Dermatol"},{"key":"5375_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/bjd\/ljad121","volume":"189","author":"S Choragudi","year":"2023","unstructured":"Choragudi\u00a0S, Yosipovitch\u00a0G (2023) Prurigo nodularis is highly linked with neural sensitization disorders of pain among hospitalized adults in the United States\u2014national inpatient sample 2016\u20132019. Br J Dermatol 189:240\u2013242","journal-title":"Br J Dermatol"},{"key":"5375_CR9","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky\u00a0W, King\u00a0BA (2017) JAK inhibitors in dermatology: the promise of a\u00a0new drug class. J\u00a0Am Acad Dermatol 76:736\u2013744","journal-title":"J Am Acad Dermatol"},{"key":"5375_CR10","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/all.14791","volume":"76","author":"A Datsi","year":"2021","unstructured":"Datsi\u00a0A, Steinhoff\u00a0M, Ahmad\u00a0F et\u00a0al (2021) Interleukin-31: the \u201citchy\u201d cytokine in inflammation and therapy. Allergy 76:2982\u20132997","journal-title":"Allergy"},{"key":"5375_CR11","doi-asserted-by":"publisher","first-page":"1022889","DOI":"10.3389\/fmed.2022.1022889","volume":"9","author":"J Deng","year":"2022","unstructured":"Deng\u00a0J, Parthasarathy\u00a0V, Marani\u00a0M et\u00a0al (2022) Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis. Front Med 9:1022889","journal-title":"Front Med"},{"key":"5375_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/pde.14464","volume":"38","author":"T Fachler","year":"2021","unstructured":"Fachler\u00a0T, Maria Faitataziadou\u00a0S, Molho-Pessach\u00a0V (2021) Dupilumab for pediatric prurigo nodularis: a\u00a0case report. Pediatr Dermatol 38:334\u2013335","journal-title":"Pediatr Dermatol"},{"key":"5375_CR13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/1346-8138.16803","volume":"50","author":"HY Fang","year":"2023","unstructured":"Fang\u00a0HY, Lian\u00a0CH (2023) The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: a\u00a0real-life observational study. J\u00a0Dermatol 50:1084\u20131087","journal-title":"J Dermatol"},{"key":"5375_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1684\/ejd.2020.3947","volume":"31","author":"M Giovannini","year":"2021","unstructured":"Giovannini\u00a0M, Mori\u00a0F, Oranges\u00a0T et\u00a0al (2021) Dupilumab treatment of prurigo nodularis in an adolescent. Eur J Dermatol 31:104\u2013106","journal-title":"Eur J Dermatol"},{"key":"5375_CR15","doi-asserted-by":"publisher","first-page":"adv00269","DOI":"10.2340\/00015555-3571","volume":"100","author":"S Gr\u00fcndel","year":"2020","unstructured":"Gr\u00fcndel\u00a0S, Pereira\u00a0MP, Storck\u00a0M et\u00a0al (2020) Analysis of 325 patients with chronic nodular prurigo: clinics, burden of disease and course of treatment. Acta Derm Venereol 100:adv269","journal-title":"Acta Derm Venereol"},{"key":"5375_CR16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.14279","volume":"30","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto\u00a0T, Nattkemper\u00a0LA, Kim\u00a0HS et\u00a0al (2021) Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol 30:804\u2013810","journal-title":"Exp Dermatol"},{"key":"5375_CR17","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1111\/jdv.18942","volume":"37","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto\u00a0T, Okuno\u00a0S, Okuzawa\u00a0M, Satoh\u00a0T (2023) Increased sensitivity to touch-evoked itch (punctate hyperknesis) in prurigo nodularis and type\u00a02 inflammation: a\u00a0cross-sectional pilot study. J\u00a0Eur Acad Dermatol Venereol 37:e789\u2013e791","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5375_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","volume":"140","author":"AH Huang","year":"2020","unstructured":"Huang\u00a0AH, Canner\u00a0JK, Khanna\u00a0R et\u00a0al (2020) Real-world prevalence of prurigo nodularis and burden of associated diseases. J\u00a0Invest Dermatol 140:480\u2013483.e4","journal-title":"J Invest Dermatol"},{"key":"5375_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1080\/09546634.2020.1853024","volume":"33","author":"H Husein-Elahmed","year":"2022","unstructured":"Husein-Elahmed\u00a0H, Steinhoff\u00a0M (2022) Dupilumab in prurigo nodularis: a\u00a0systematic review of current evidence and analysis of predictive factors to response. J\u00a0Dermatolog Treat 33:1547\u20131553","journal-title":"J Dermatolog Treat"},{"key":"5375_CR20","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.13827","volume":"31","author":"KM J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen\u00a0KM, Egeberg\u00a0A, Gislason\u00a0GH et\u00a0al (2017) Anxiety, depression and suicide in patients with prurigo nodularis. J\u00a0Eur Acad Dermatol Venereol 31:e106\u2013e107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5375_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam\u00a0SJ (2022) Nemolizumab: first approval. Drugs 82:1143\u20131150","journal-title":"Drugs"},{"key":"5375_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ITT.S316602","volume":"11","author":"A Labib","year":"2022","unstructured":"Labib\u00a0A, Ju\u00a0T, Vander Does\u00a0A, Yosipovitch\u00a0G (2022) Immunotargets and therapy for prurigo nodularis. Immunotargets Ther 11:11\u201321","journal-title":"Immunotargets Ther"},{"key":"5375_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp\u00a0K, Szepietowski\u00a0JC, Kircik\u00a0L et\u00a0al (2021) Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase\u00a03, randomized, double-blind studies. J\u00a0Am Acad Dermatol 85:863\u2013872","journal-title":"J Am Acad Dermatol"},{"key":"5375_CR24","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/exd.13343","volume":"26","author":"MP Pereira","year":"2017","unstructured":"Pereira\u00a0MP, Pogatzki-Zahn\u00a0E, Snels\u00a0C et\u00a0al (2017) There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations. Exp Dermatol 26:969\u2013971","journal-title":"Exp Dermatol"},{"key":"5375_CR25","doi-asserted-by":"publisher","first-page":"adv00403","DOI":"10.2340\/00015555-3726","volume":"101","author":"MP Pereira","year":"2021","unstructured":"Pereira\u00a0MP, Zeidler\u00a0C, Wallengren\u00a0J et\u00a0al (2021) Chronic nodular prurigo: a\u00a0European cross-sectional study of patient perspectives on therapeutic goals and satisfaction. Acta Derm Venereol 101:adv403","journal-title":"Acta Derm Venereol"},{"key":"5375_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jid.2019.05.029","volume":"140","author":"EM Pogatzki-Zahn","year":"2020","unstructured":"Pogatzki-Zahn\u00a0EM, Pereira\u00a0MP, Cremer\u00a0A et\u00a0al (2020) Peripheral sensitization and loss of descending inhibition is a\u00a0hallmark of chronic pruritus. J\u00a0Invest Dermatol 140:203\u2013211.e4","journal-title":"J Invest Dermatol"},{"key":"5375_CR27","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin\u00a0D, Passeron\u00a0T, Pandya\u00a0AG et\u00a0al (2022) Two phase\u00a03, randomized, controlled trials of ruxolitinib cream for vitiligo. N\u00a0Engl J Med 387:1445\u20131455","journal-title":"N Engl J Med"},{"key":"5375_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1365-2133.2011.10306.x","volume":"165","author":"B Schuhknecht","year":"2011","unstructured":"Schuhknecht\u00a0B, Marziniak\u00a0M, Wissel\u00a0A et\u00a0al (2011) Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a\u00a0potential sign of subclinical cutaneous neuropathy. Br J Dermatol 165:85\u201391","journal-title":"Br J Dermatol"},{"key":"5375_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/exd.14678","volume":"32","author":"Y Shao","year":"2023","unstructured":"Shao\u00a0Y, Zhu\u00a0Y, Xiao\u00a0Z et\u00a0al (2023) RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching. Exp Dermatol 32:30\u201340","journal-title":"Exp Dermatol"},{"key":"5375_CR30","doi-asserted-by":"publisher","first-page":"101826","DOI":"10.1016\/j.eclinm.2023.101826","volume":"57","author":"H Sofen","year":"2023","unstructured":"Sofen\u00a0H, Bissonnette\u00a0R, Yosipovitch\u00a0G et\u00a0al (2023) Efficacy and safety of vixarelimab, a\u00a0human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a\u00a0randomised, double-blind, placebo-controlled, phase\u00a02a\u00a0study. EClinicalMedicine 57:101826","journal-title":"EClinicalMedicine"},{"key":"5375_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad162.056","author":"S St\u00e4nder","year":"2023","unstructured":"St\u00e4nder\u00a0S, Yosipovitch\u00a0G, Legat\u00a0F et\u00a0al (2023) 436 nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a\u00a0phase\u00a03\u00a0trial (OLYMPIA 2). Br J Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljad162.056","journal-title":"Br J Dermatol"},{"key":"5375_CR32","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/ddg.14830_g","volume":"20","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder\u00a0S, Zeidler\u00a0C, Augustin\u00a0M et\u00a0al (2022) S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus. J\u00a0Dtsch Dermatol Ges 20:1386\u20131402","journal-title":"J Dtsch Dermatol Ges"},{"key":"5375_CR33","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/jdv.17111","volume":"35","author":"M Storck","year":"2021","unstructured":"Storck\u00a0M, Sandmann\u00a0S, Bruland\u00a0P et\u00a0al (2021) Pruritus intensity scales across Europe: a\u00a0prospective validation study. J\u00a0Eur Acad Dermatol Venereol 35:1176\u20131185","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5375_CR34","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/bjd.13492","volume":"172","author":"A Stumpf","year":"2015","unstructured":"Stumpf\u00a0A, St\u00e4nder\u00a0S, Warlich\u00a0B et\u00a0al (2015) Relations between the characteristics and psychological comorbidities of chronic pruritus differ between men and women: women are more anxious than men. Br J Dermatol 172:1323\u20131328","journal-title":"Br J Dermatol"},{"key":"5375_CR35","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.jid.2022.02.010","volume":"142","author":"N Sutaria","year":"2022","unstructured":"Sutaria\u00a0N, Alphonse\u00a0MP, Roh\u00a0YS et\u00a0al (2022) Cutaneous transcriptomics identifies fibroproliferative and neurovascular gene dysregulation in prurigo nodularis compared with psoriasis and atopic dermatitis. J\u00a0Invest Dermatol 142:2537\u20132540","journal-title":"J Invest Dermatol"},{"key":"5375_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","volume":"149","author":"LC Tsoi","year":"2022","unstructured":"Tsoi\u00a0LC, Hacini-Rachinel\u00a0F, Fogel\u00a0P et\u00a0al (2022) Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J\u00a0Allergy Clin Immunol 149:1329\u20131339","journal-title":"J Allergy Clin Immunol"},{"key":"5375_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/derm.2022.0065","volume":"34","author":"A Vander Does","year":"2023","unstructured":"Vander Does\u00a0A, Yosipovitch\u00a0G (2023) Failure of dupilimab with severe prurigo nodularis that responded well to abrocitinib. Dermatitis 34:567","journal-title":"Dermatitis"},{"key":"5375_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/jdv.17816","volume":"36","author":"E Weisshaar","year":"2022","unstructured":"Weisshaar\u00a0E, Szepietowski\u00a0JC, Bernhard\u00a0JD et\u00a0al (2022) Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a\u00a0phase\u00a02 randomized controlled trial with an open-label extension phase. J\u00a0Eur Acad Dermatol Venereol 36:453\u2013461","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5375_CR39","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","volume":"83","author":"KA Williams","year":"2020","unstructured":"Williams\u00a0KA, Huang\u00a0AH, Belzberg\u00a0M, Kwatra\u00a0SG (2020) Prurigo nodularis: pathogenesis and management. J\u00a0Am Acad Dermatol 83:1567\u20131575","journal-title":"J Am Acad Dermatol"},{"key":"5375_CR40","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch\u00a0G, Mollanazar\u00a0N, St\u00e4nder\u00a0S et\u00a0al (2023) Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase\u00a03\u00a0trials. Nat Med 29:1180\u20131190","journal-title":"Nat Med"},{"key":"5375_CR41","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/jdv.16929","volume":"35","author":"C Zeidler","year":"2021","unstructured":"Zeidler\u00a0C, Pereira\u00a0MP, Dugas\u00a0M et\u00a0al (2021) The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: a\u00a0comparative, retrospective, explorative statistical analysis of 4,484 patients in a\u00a0real-world cohort. J\u00a0Eur Acad Dermatol Venereol 35:738\u2013743","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05375-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05375-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05375-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T09:02:55Z","timestamp":1722848575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05375-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5375"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05375-y","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"assertion":[{"value":"22 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0St\u00e4nder ist Pr\u00fcf\u00e4rztin f\u00fcr Celldex, Clexio, Dermasence, Galderma, GSK, Incyte, Kiniksa, Novartis, Sanofi, Trevi. Sie ist Beraterin und\/oder Mitglied von Beir\u00e4ten f\u00fcr AbbVie, Almirall, Beiersdorf, Benevolent, Bionorica, Cara, Celgene, Clexio, DS Biopharma, Eli Lilly, Escient, Galderma, Kiniksa, Klinge Pharma, Leo Pharma, Maruho, Menlo, P.G.\u00a0Unna Academy, Pfizer, Sanofi, Symbio Research, Trevi, Vanda, Vifor, WebMD. C.\u00a0Zeidler ist oder war Beraterin, Referentin oder Pr\u00fcferin f\u00fcr Novartis, Janssen, Pfizer, UCB, Lilly, AbbVie, Boehringer Ingelheim, Sanofi, Regeneron, Leo, Galderma, Dermasence, Beiersdorf, Unna Akademie. Sie war Beraterin f\u00fcr Sanofi und Almirall. F.\u00a0Witte gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}